Aneustat™ was designed with systems biology considerations to act on the heterogeneous characteristics of cancer cells, the multiple cell types in the tumor microenvironment and the patient's immune/inflammatory system.
The drug's action is due to a Multifunctional Multitargeted (MFMT™) mechanism that overcomes the widely recognized limitations of monovalent and single targeted drugs, including limited effectiveness, serious side effects and the inevitable onset of drug resistance.
Aneustat™ is orally delivered and non-toxic.
Aneustat™ is entering phase II clinical trials for prostate cancer, the most prevalent cancer in American men.
Omnitura believes that the benefits of Aneustat™ will stimulate a paradigm shift in cancer treatment, and whether used alone or in combination with other cancer treatments, will become the foundational drug in the war on cancer.
Contact us to learn more.